Literature DB >> 10406221

Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide.

S C Hall1, M M Tan, J J Leonard, C L Stevenson.   

Abstract

The effect of solvent on the rate of leuprolide degradation and on the structure of the degradation products was explored. Leuprolide solutions (370 mg/mL) were prepared in water and dimethyl sulfoxide (DMSO) for delivery in DUROS osmotic implants. Both solvent systems demonstrated better than 90% stability after 1 year at 37 degrees C, where the DMSO formulation afforded better stability than the aqueous formulation and was used in subsequent clinical trials. The rate of leuprolide degradation in DMSO was also observed to accelerate with increasing moisture content, indicating that the aprotic solvent minimized chemical degradation. Interestingly, leuprolide degradation products varied with formulation vehicle. The proportions of leuprolide degradation products observed to form in water and DMSO at 37 degrees C were hydrolysis > aggregation > isomerization > oxidation and aggregation > oxidation > hydrolysis > isomerization, respectively. Specifically, more N-terminal hydrolysis and acetylation were observed under aqueous conditions, and increased Trp oxidation and Ser beta-elimination were seen under non-aqueous conditions. Furthermore, the major chemical degradation pathway changed with temperature in the DMSO formulation (decreasing oxidation with increasing temperature), but not in the aqueous formulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406221     DOI: 10.1034/j.1399-3011.1999.00069.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  5 in total

1.  Effect of excipients on PLGA film degradation and the stability of an incorporated peptide.

Authors:  M L Houchin; S A Neuenswander; E M Topp
Journal:  J Control Release       Date:  2006-12-01       Impact factor: 9.776

2.  A short term quality control tool for biodegradable microspheres.

Authors:  Susan D'Souza; Jabar A Faraj; Rossella Dorati; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2014-02-12       Impact factor: 3.246

3.  DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months.

Authors:  Catherine M Rohloff; Thomas R Alessi; Bing Yang; Janice Dahms; John P Carr; Scott D Lautenbach
Journal:  J Diabetes Sci Technol       Date:  2008-05

4.  Dosage form development, in vitro release kinetics, and in vitro-in vivo correlation for leuprolide released from an implantable multi-reservoir array.

Authors:  James H Prescott; Timothy J Krieger; Sara Lipka; Mark A Staples
Journal:  Pharm Res       Date:  2007-03-27       Impact factor: 4.580

5.  Drug Repurposing by Simulating Flow Through Protein-Protein Interaction Networks.

Authors:  M Manczinger; V Á Bodnár; B T Papp; S B Bolla; K Szabó; B Balázs; E Csányi; E Szél; G Erős; L Kemény
Journal:  Clin Pharmacol Ther       Date:  2017-07-29       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.